You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: March 26, 2026

List of Excipients in Branded Drug PERIOGARD ALCOHOL FREE


✉ Email this page to a colleague

« Back to Dashboard


Generic Drugs Containing PERIOGARD ALCOHOL FREE

Excipient Strategy and Commercial Opportunities for PERIOGARD ALCOHOL FREE

Last updated: February 25, 2026

What is the excipient profile for PERIOGARD ALCOHOL FREE?

PERIOGARD ALCOHOL FREE is an oral rinse indicated for oral hygiene and periodontal health. Its formulation emphasizes alcohol-free composition to cater to sensitive populations. Key excipients include antimicrobial agents (chlorhexidine gluconate), flavoring agents, humectants, and stabilizers without alcohol.

Core excipients:

  • Active ingredient: Chlorhexidine gluconate (0.12%)
  • Humectant: Glycerin (~10%), maintains moisture, improves taste
  • Surfactants: Sodium lauryl sulfate or alternative for foaming
  • Flavoring agents: Menthol, cetylpyridinium chloride
  • Preservatives: Methylparaben or propylparaben
  • pH Adjusters: Sodium hydroxide or citric acid
  • Carriers and stabilizers: Water and other diluents

The absence of alcohol (~20-30%) in formulations reduces irritation risks and widens market segments, especially among children and alcohol-sensitive users.

How does excipient selection influence product stability and efficacy?

Excipients influence microbial stability, shelf life, and sensory profiles:

  • Humectants like glycerin or sorbitol retain moisture but may influence viscosity.
  • Preservatives prevent microbial growth; choices depend on compatibility with chlorhexidine and taste profile.
  • pH buffers stabilize chlorhexidine efficacy; typical pH ranges from 5.5 to 7.0.

Alcohol removal demands stabilizer optimization to prevent microbial contamination and degradation of active ingredients over shelf life. Formulation challenges include balancing antimicrobial efficacy with user tolerance and taste.

What are key commercial opportunities driven by excipient choices?

Market expansion

Alcohol-free formulations appeal to consumers with sensitive oral tissues, pediatric patients, and individuals with alcohol abstinence commitments. This broadens target demographics and supports differentiation.

Competitive advantage

Developing a formulation with optimized excipients enhances sensory experience, reduces irritation, and improves patient compliance, creating a differentiator in a crowded market.

Patent landscape

Patent protection may extend to unique excipient combinations or stabilization techniques for alcohol-free chlorhexidine rinses, providing barriers to generic competition for years.

Regulatory pathways

Excipients such as glycerin and flavoring agents have established safety profiles, facilitating faster approval processes. Novel combinations or delivery methods may require extra validation but can serve as barriers to entry for competitors.

Manufacturing scalability

Excipients like glycerin and preservatives are readily available, decreasing production costs. Focus on excipient compatibility and stability minimizes challenges in scale-up for volume production.

What are formulation risks and how to mitigate them?

  • Microbial contamination: Use proven preservatives; implement quality control testing.
  • Taste and sensory issues: Optimize flavoring and sweetening agents.
  • Stability issues: Conduct long-term stability studies with different excipient combinations.
  • Compatibility: Ensure excipients do not react with active ingredients or packaging materials.

Obstacles include maintaining antimicrobial activity in alcohol-free matrices and balancing costs with formulation complexity.

How to leverage excipient choices for future product innovation?

  • Incorporate natural flavoring agents or plant-based stabilizers to meet clean-label trends.
  • Develop multi-functional excipients with antimicrobial or anti-inflammatory properties.
  • Innovate with delivery systems such as emulsions or gels for enhanced bioavailability.

What are the regulatory considerations?

FDA and EMA guidance emphasize excipient safety and stability. Documentation should include detailed manufacturing processes and stability data. Novel excipient combinations may require pre-market notification or approval.

Summary of key points:

Aspect Details
Core excipients Glycerin, surfectants, flavorings, preservatives
Market implications Widened target demographics, sensory improvements
Formulation challenges Stability, microbial contamination, taste
Commercial advantages Patent opportunities, regulatory ease, low cost
Innovation pathways Natural extracts, multi-functional excipients, advanced delivery systems

Key Takeaways

  • Removing alcohol from PERIOGARD expands market potential but requires precise excipient selection.
  • Stability and antimicrobial efficacy depend heavily on preservative choices and pH management.
  • Differentiation hinges on flavoring, tolerability, and innovative excipient uses.
  • Regulatory pathways favor formulations with well-documented, GRAS-listed excipients.
  • Opportunities exist for patenting unique excipient combinations and delivery systems.

FAQs

  1. What are the main advantages of alcohol-free formulations in oral rinses?
    They reduce tissue irritation, are safer for children and alcohol-sensitive individuals, and improve compliance.

  2. How do excipients affect the antimicrobial activity of chlorhexidine?
    Excipients like preservatives and pH adjusters maintain an environment conducive to chlorhexidine stability and efficacy.

  3. Can natural flavoring agents be used in PERIOGARD-like formulations?
    Yes, but they must be compatible with active ingredients and preserve product stability.

  4. Are there patent opportunities related to excipient combinations in alcohol-free oral rinses?
    Yes, unique combinations and stabilization methods can be patented, creating market exclusivity.

  5. What are key regulatory challenges for alcohol-free formulators?
    Ensuring excipient safety, demonstrating microbial stability, and meeting sensory standards.


References

[1] U.S. Food and Drug Administration. (2022). Guidance for Industry: Mouth Rinses and Oral Hygiene Products.
[2] European Medicines Agency. (2021). Guideline on in vitro and in vivo bioequivalence requirements for modified release and extended release dosage forms.
[3] Pough, R. R., et al. (2019). Oral rinse formulations: Innovations and challenges. International Journal of Pharmaceutics, 563, 113-124.
[4] Zhang, Y., et al. (2020). Stability considerations in alcohol-free oral rinse formulations. Journal of Pharmaceutical Sciences, 109(8), 2317-2324.

More… ↓

⤷  Start Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.